Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• RubovszkyGHorváthZRecent Advances in the Neoadjuvant Treatment of Breast CancerJ Breast Cancer201720211913128690648
   PubMed Web of Science ®Google Scholar
• CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
   PubMed Web of Science ®Google Scholar
• UntchMFaschingPAKonecnyGEPathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groupsJ Clin Oncol201129253351335721788566
   PubMed Web of Science ®Google Scholar
• Uriarte-PintoMEscolano-PueyoAGimeno-BallesterVPascual-MartinezOAbad-SazatornilMRAgustin-FerrandezMJTrastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancerInt J Clin Pharm201638244645326951122
   PubMed Web of Science ®Google Scholar
• GoldhirschAWoodWCCoatesASPanel membersStrategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Ann Oncol20112281736174721709140
   PubMed Web of Science ®Google Scholar
• GoldhirschAWinerEPCoatesASPanel membersPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Ann Oncol20132492206222323917950
   PubMed Web of Science ®Google Scholar
• BuzdarAUIbrahimNKFrancisDSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol200523163676368515738535
   PubMed Web of Science ®Google Scholar
• ValachisAMauriDPolyzosNPChlouverakisGMavroudisDGeorgouliasVTrastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysisBreast201120648549021784637
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementAnn Intern Med20091514264269W6419622511
   PubMed Web of Science ®Google Scholar
• BoothAClarkeMDooleyGThe nuts and bolts of PROSPERO: an international prospective register of systematic reviewsSyst Rev20121222587842
   PubMedGoogle Scholar
• BuzdarAUValeroVIbrahimNKNeoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimenClin Cancer Res200713122823317200359
   PubMed Web of Science ®Google Scholar
• HuangLChenSYangWEfficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II–III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trialOncotarget2015621186831869226084292
   PubMedGoogle Scholar
• BayraktarSGonzalez-AnguloAMLeiXEfficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancerCancer201211892385239321953213
   PubMed Web of Science ®Google Scholar
• PizzutiLBarbaMGiannarelliDNeoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT TrialJ Cell Physiol2016231112541254727187274
   PubMed Web of Science ®Google Scholar
• DawoodSGonzalez-AnguloAMPeintingerFEfficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experienceCancer200711061195120017647266
   PubMed Web of Science ®Google Scholar
• WenzelCHussianDBartschRPreoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot studyJ Cancer Res Clin Oncol2004130740040415168107
   PubMed Web of Science ®Google Scholar
• GaviláJGuerreroÁClimentMÁEfficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practiceInt J Clin Oncol201520348048925011497
   PubMed Web of Science ®Google Scholar
• UntchMRezaiMLoiblSNeoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyJ Clin Oncol201028122024203120308670
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet2010375971237738420113825
   PubMed Web of Science ®Google Scholar
• UntchMLoiblSBischoffJGerman Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study GroupLapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialLancet Oncol201213213514422257523
   PubMed Web of Science ®Google Scholar
• TuxenMKColdSTangeUBBalslevENielsenDLPhase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosph-amide ± trastuzumab followed by docetaxel in locally advanced breast cancerActa Oncol201453101440144524991893
   PubMed Web of Science ®Google Scholar
• Hamy-PetitASBelinLBonsang-KitzisHPathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortBr J Cancer20161141445226657653
   PubMed Web of Science ®Google Scholar
• PetrelliFBorgonovoKCabidduMGhilardiMBarniSNeoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trialsAnticancer Drugs201122212813521218604
   PubMed Web of Science ®Google Scholar
• ChenYYWangLWChenFFWuBBXiongBEfficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysisExp Ther Med20161151721173327168794
   PubMed Web of Science ®Google Scholar
• ClarkeMCollinsRDarbySEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trialsLancet200536695032087210616360786
   PubMed Web of Science ®Google Scholar
• van MaarenMCde MunckLde BockGH10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based studyLancet Oncol20161781158117027344114
   PubMed Web of Science ®Google Scholar
• FriedrichMJCardiotoxicity concerns prompt data review in breast cancer trialJ Natl Cancer Inst200294965065111983752
   PubMedGoogle Scholar
• GuenanciaCLefebvreACardinaleDObesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-AnalysisJ Clin Oncol201634263157316527458291
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDGutheilJCEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• ChenXYeGZhangCLiXShenKNon-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT studyChin J Cancer Res201628656156928174484
   PubMed Web of Science ®Google Scholar